The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab — Antonio D’Alessio (2023) | RDL Network
The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Y. Wu, Anwaar Saeed, Brooke Wietharn, Lorenza Rimassa, Angelo Pirozzi, Antonella Cammarota, Tiziana Pressiani, Matthias Pinter, Lorenz Balcar, Yi‐Hsiang Huang, Aman Mehan, Samuel Phen, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Adel Samson, Peter R. Galle, Masatoshi Kudo, Giulia Francesca Manfredi, Ciro Celsa, Nichola Awosika, Alessio Cortellini, Amit G. Singal, Rohini Sharma, Hong Jae Chon, Francesco Tovoli, Fabio Piscaglia, David J. Pinato, Antonio D’Alessio
Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, F. Piscaglia, Massimo Iavarone, Emiliano Tamburini, Giuseppe Cabibbo, Marianna Silletta, Stefano Cascinu, Mario Scartozzi, A. Casadei Gardini
Discussion(0)
No comments yet. Be the first to comment.